NasdaqGM:HRMYPharmaceuticals
Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives
Harmony Biosciences Holdings (HRMY) opened Q1 2026 with total revenue of US$215.4 million and basic EPS of US$0.56, setting a clear reference point against a trailing twelve month EPS of US$2.53 on US$899.1 million of revenue. Over recent quarters the company has seen quarterly revenue move from US$184.7 million in Q1 2025 to a peak of US$243.8 million in Q4 2025, while basic EPS has shifted from US$0.79 to US$0.39 over the same span. This puts the latest print into sharper context for...